NRIX: Major Roche deal accelerates BTK degrader's global development and multi-billion dollar potential
A landmark Roche partnership expands the clinical and commercial reach of a BTK degrader, with pivotal trials underway and a strong safety profile supporting broad development in oncology and autoimmune diseases. Additional partnered programs and novel DAC technology further enhance future growth p…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.